Acute Kidney Dysfunction in COVID-19 and Non-COVID-19 Related ARDS (URICOV)

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Completed

Conditions: COVID-19 Acute Respiratory Distress Syndrome; Acute Kidney Injury Due to COVID-19

Treatments: Other: Data collection

Study type: Observational

Funder types: Other

Identifiers

NCT05699889

RCAPHM20_0177

Details and patient eligibility

About

In addition to respiratory involvement, SARS-CoV 2, the virus responsible for coronavirus 2019 or Covid-19, appears to be responsible for renal involvement such as acute renal failure or proteinuria, so the mechanisms are not known at this time. The consequences of Covid-19 on renal function in the short and long term are not known.

It is important to be able to better document these renal impairments to understand the mechanisms of this disease.

The main objective of this study is to describe the prevalence of Covid-19-related renal damage (acute renal failure, proteinuria, microalbuminuria, hematuria) in a large cohort of patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment.

The other objectives will be to evaluate in this cohort the impact of these renal impairments on the severity of the Covid-19 disease, and to compare them to the renal impairments of patients in intensive care for acute respiratory distress syndrome (ARDS) due to other respiratory diseases.

Blood and urine samples will be taken at the time of intubation in all critically ill patients with respiratory distress requiring mechanical ventilation for Covid-19 or other cause of respiratory distress with PaO2/FiO2 ratio < 300.

Patients will be followed for the duration of their ICU and hospital stay. Data will be collected prospectively in three ICUs in the University Hospitals of Marseille.

Enrollment: 130 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Displaying acute respiratory distress Needing invasive mechanical ventilation

  • With PaO2/FiO2 ratio < 300 after orotracheal intubation

Exclusion criteria

• Patients in ICU following thoracic surgery or lung transplantation
• Patients with cardiogenic pulmonary oedema
• Patients with end stage kidney disease
• Moribund patients

Trial design

130 participants in 2 patient groups

Patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment.

Treatment:

Other: Data collection

Patients in intensive care without SARS-CoV 2 infection with severe respiratory impairment.

Treatment:

Other: Data collection